Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

The blockade of serotonin (5-HT) and norepinephrine (NE) transporters in vitro and in vivo by the dual 5-HT/NE reuptake inhibitors duloxetine and venlafaxine was compared. Duloxetine inhibited binding to the human NE and 5-HT transporters with Ki values of 7.5 and 0.8 nM, respectively, and with a Ki ratio of 9. Venlafaxine inhibited binding to the human NE and 5-HT transporters with Ki values of 2480 and 82 nM, respectively, and with a Ki ratio of 30. Duloxetine inhibited ex vivo binding to rat 5-HT transporters and NE transporters with ED50 values of 0.03 and 0.7 mg/kg, respectively, whereas venlafaxine had ED50 values of 2 and 54 mg/kg, respectively. The depletion of rat brain 5-HT by p-chloramphetamine and depletion of rat hypothalamic NE by 6-hydroxydopamine was blocked by duloxetine with ED50 values of 2.3 and 12 mg/kg, respectively. Venlafaxine had ED50 values of 5.9 and 94 mg/kg for blocking p-chloramphetamine– and 6-hydroxydopamine–induced monoamine depletion, respectively. Thus, duloxetine more potently blocks 5-HT and NE transporters in vitro and in vivo than venlafaxine.

[1]  I. Anderson,et al.  Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. , 2000, Journal of affective disorders.

[2]  C. Montigny,et al.  Current advances and trends in the treatment of depression. , 1994, Trends in pharmacological sciences.

[3]  T. Branchek,et al.  Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. , 1993, The Journal of biological chemistry.

[4]  J. Nelson Augmentation strategies with serotonergic-noradrenergic combinations. , 1998, The Journal of clinical psychiatry.

[5]  S. Troy,et al.  Pharmacokinetic Interaction Between Multiple‐Dose Venlafaxine and Single‐Dose Lithium , 1996, Journal of clinical pharmacology.

[6]  G. Debonnel,et al.  Venlafaxine: Discrepancy between in vivo 5‐HT and NE reuptake blockade and affinity for reuptake sites , 1999, Synapse.

[7]  J. Mendels,et al.  Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. , 1993, Psychopharmacology bulletin.

[8]  J. Schildkraut,et al.  The catecholamine hypothesis of affective disorders. A review of supporting evidence. , 1967, International journal of psychiatry.

[9]  K. Bergmann,et al.  Combination Treatment with Noradrenalin and Serotonin Reuptake Inhibitors in Resistant Depression , 1992, British Journal of Psychiatry.

[10]  C. Mazure,et al.  A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. , 1991, Archives of general psychiatry.

[11]  D. Nelson,et al.  Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences. , 1996, The Journal of pharmacology and experimental therapeutics.

[12]  F. Bloom,et al.  Psychopharmacology: The Fourth Generation of Progress , 1995 .

[13]  E. Richelson,et al.  Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. , 1993, Life sciences.

[14]  T. Branchek,et al.  Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Wong,et al.  Antagonism of Serotonin 5‐HT1A Receptors Potentiates the Increases in Extracellular Monoamines Induced by Duloxetine in Rat Hypothalamus , 1996, Journal of neurochemistry.

[16]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[17]  B. Walsh,et al.  Tricyclic nonresponders: phenomenology and treatment. , 1986, The American journal of psychiatry.

[18]  R. Fuller,et al.  Selective inhibition of monoamine oxidase in rat brain mitochondria. , 1970, Biochemical pharmacology.

[19]  M. Millan,et al.  WAY 100,635 enhances both the 'antidepressant' actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex. , 1998, European journal of pharmacology.

[20]  A. Katoh,et al.  Behavioral and electroencephalographic properties of duloxetine (LY248686), a reuptake inhibitor of norepinephrine and serotonin, in mice and rats. , 1995, The Journal of pharmacology and experimental therapeutics.

[21]  I. Lucki,et al.  Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test , 1998, Psychopharmacology.

[22]  M. Millan,et al.  Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. , 1997, Journal of neurochemistry.

[23]  J. Haskins,et al.  Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. , 1986, Biochemical pharmacology.

[24]  M. Berk,et al.  An open‐label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM‐III-R major depressive disorder , 1997 .

[25]  D. Wong,et al.  Simultaneous Increases of Extracellular Monoamines in Microdialysates from Hypothalamus of Conscious Rats by Duloxetine, a Dual Serotonin and Norepinephrine Uptake Inhibitor , 1995, Neuropsychopharmacology.

[26]  G. Aghajanian,et al.  Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. , 1990, Archives of general psychiatry.

[27]  K. Perry,et al.  Effects of buspirone and its metabolite, 1-(2-pyrimidinyl)piperazine, on brain monoamines and their metabolites in rats. , 1989, The Journal of pharmacology and experimental therapeutics.

[28]  F. Artigas Selective Serotonin/Noradrenal Reuptake Inhibitors (SNRIs) , 1995 .

[29]  F. Monsma,et al.  Functional and Radioligand Binding Characterization of Rat 5-HT6 Receptors Stably Expressed in HEK293 Cells , 1997, Neuropharmacology.

[30]  D. Wong,et al.  LY248686, A New Inhibitor of Serotonin and Norepinephrine Uptake , 1993, Neuropsychopharmacology.

[31]  R. Fuller,et al.  Effects of duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice. , 1994, The Journal of pharmacology and experimental therapeutics.

[32]  D. Wong,et al.  Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. , 1995, Life sciences.

[33]  T. Branchek,et al.  Expression and pharmacological characterization of a canine 5-hydroxytryptamine1D receptor subtype. , 1991, Molecular pharmacology.

[34]  R. Salomon,et al.  Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. , 1993, Psychopharmacology bulletin.

[35]  J. Feighner,et al.  Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. , 1994, The Journal of clinical psychiatry.

[36]  A. Gobert,et al.  α2‐Adrenergic Receptor Blockade Markedly Potentiates Duloxetine‐ and Fluoxetine‐Induced Increases in Noradrenaline, Dopamine, and Serotonin Levels in the Frontal Cortex of Freely Moving Rats , 1997 .

[37]  J. Rosenbaum,et al.  Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. , 1989, The Journal of clinical psychiatry.

[38]  G. Debonnel,et al.  Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. , 1998, European journal of pharmacology.

[39]  C. de Montigny,et al.  Blockade of the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. , 1996, The Journal of pharmacology and experimental therapeutics.

[40]  M. Ikeda,et al.  Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. , 1995, The Journal of pharmacology and experimental therapeutics.

[41]  H. Kao,et al.  Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. Blakely,et al.  Pharmacological profile of antidepressants and related compounds at human monoamine transporters. , 1997, European journal of pharmacology.

[43]  D. Wong Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. , 1998, Expert opinion on investigational drugs.